Amgen reported Phase 3 VESALIUS-CV trial data showing Repatha (evolocumab) reduced the risk of death by 20% in high-risk adults (for a first heart attack or stroke) when added to statins or other LDL-C therapies. The results strengthen the efficacy profile of its PCSK9 inhibitor in primary prevention-style patients. Overall, the trial readout is a meaningful positive catalyst for AMGN’s long-term outlook.
Amgen reported Phase 3 VESALIUS-CV trial data showing Repatha (evolocumab) reduced the risk of death by 20% in high-risk adults (for a first heart attack or stroke) when added to statins or other LDL-C therapies. The results strengthen the efficacy profile of its PCSK9 inhibitor in primary prevention-style patients. Overall, the trial readout is a meaningful positive catalyst for AMGN’s long-term outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
